These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
196 related articles for article (PubMed ID: 34059639)
1. Fosciclopirox suppresses growth of high-grade urothelial cancer by targeting the γ-secretase complex. Weir SJ; Dandawate P; Standing D; Bhattacharyya S; Ramamoorthy P; Rangarajan P; Wood R; Brinker AE; Woolbright BL; Tanol M; Ham T; McCulloch W; Dalton M; Reed GA; Baltezor MJ; Jensen RA; Taylor JA; Anant S Cell Death Dis; 2021 May; 12(6):562. PubMed ID: 34059639 [TBL] [Abstract][Full Text] [Related]
2. Preclinical Pharmacokinetics of Fosciclopirox, a Novel Treatment of Urothelial Cancers, in Rats and Dogs. Weir SJ; Wood R; Schorno K; Brinker AE; Ramamoorthy P; Heppert K; Rajewski L; Tanol M; Ham T; McKenna MJ; McCulloch W; Dalton M; Reed GA; Jensen RA; Baltezor MJ; Anant S; Taylor JA J Pharmacol Exp Ther; 2019 Aug; 370(2):148-159. PubMed ID: 31113837 [TBL] [Abstract][Full Text] [Related]
3. Reposition of the Fungicide Ciclopirox for Cancer Treatment. Huang Z; Huang S Recent Pat Anticancer Drug Discov; 2021; 16(2):122-135. PubMed ID: 33573561 [TBL] [Abstract][Full Text] [Related]
5. Effects of the antifungal agent ciclopirox in HPV-positive cancer cells: Repression of viral E6/E7 oncogene expression and induction of senescence and apoptosis. Braun JA; Herrmann AL; Blase JI; Frensemeier K; Bulkescher J; Scheffner M; Galy B; Hoppe-Seyler K; Hoppe-Seyler F Int J Cancer; 2020 Jan; 146(2):461-474. PubMed ID: 31603527 [TBL] [Abstract][Full Text] [Related]
6. Breast intraductal nanoformulations for treating ductal carcinoma in situ I: Exploring metal-ion complexation to slow ciclopirox release, enhance mammary persistence and efficacy. Al-Zubaydi F; Gao D; Kakkar D; Li S; Adler D; Holloway J; Szekely Z; Gu Z; Chan N; Kumar S; Love S; Sinko PJ J Control Release; 2020 Jul; 323():71-82. PubMed ID: 32302762 [TBL] [Abstract][Full Text] [Related]
7. Ciclopirox targets cellular bioenergetics and activates ER stress to induce apoptosis in non-small cell lung cancer cells. Lu J; Li Y; Gong S; Wang J; Lu X; Jin Q; Lu B; Chen Q Cell Commun Signal; 2022 Mar; 20(1):37. PubMed ID: 35331268 [TBL] [Abstract][Full Text] [Related]
8. Chelation of intracellular iron with the antifungal agent ciclopirox olamine induces cell death in leukemia and myeloma cells. Eberhard Y; McDermott SP; Wang X; Gronda M; Venugopal A; Wood TE; Hurren R; Datti A; Batey RA; Wrana J; Antholine WE; Dick JE; Schimmer AD Blood; 2009 Oct; 114(14):3064-73. PubMed ID: 19589922 [TBL] [Abstract][Full Text] [Related]
9. Gene Expression Signature-Based Approach Identifies Antifungal Drug Ciclopirox As a Novel Inhibitor of HMGA2 in Colorectal Cancer. Huang YM; Cheng CH; Pan SL; Yang PM; Lin DY; Lee KH Biomolecules; 2019 Nov; 9(11):. PubMed ID: 31684108 [TBL] [Abstract][Full Text] [Related]
10. Superior efficacy of the antifungal agent ciclopirox olamine over gemcitabine in pancreatic cancer models. Mihailidou C; Papakotoulas P; Papavassiliou AG; Karamouzis MV Oncotarget; 2018 Feb; 9(12):10360-10374. PubMed ID: 29535812 [TBL] [Abstract][Full Text] [Related]
11. Ciclopirox activates PERK-dependent endoplasmic reticulum stress to drive cell death in colorectal cancer. Qi J; Zhou N; Li L; Mo S; Zhou Y; Deng Y; Chen T; Shan C; Chen Q; Lu B Cell Death Dis; 2020 Jul; 11(7):582. PubMed ID: 32719342 [TBL] [Abstract][Full Text] [Related]
12. Ciclopirox drives growth arrest and autophagic cell death through STAT3 in gastric cancer cells. Chen L; Chen D; Li J; He L; Chen T; Song D; Shan S; Wang J; Lu X; Lu B Cell Death Dis; 2022 Nov; 13(11):1007. PubMed ID: 36443287 [TBL] [Abstract][Full Text] [Related]
13. Ciclopirox olamine inhibits mTORC1 signaling by activation of AMPK. Zhou H; Shang C; Wang M; Shen T; Kong L; Yu C; Ye Z; Luo Y; Liu L; Li Y; Huang S Biochem Pharmacol; 2016 Sep; 116():39-50. PubMed ID: 27396756 [TBL] [Abstract][Full Text] [Related]
14. Breast intraductal nanoformulations for treating ductal carcinoma in situ II: Dose de-escalation using a slow releasing/slow bioconverting prodrug strategy. Al-Zubaydi F; Gao D; Kakkar D; Li S; Holloway J; Szekely Z; Chan N; Kumar S; Sabaawy HE; Love S; Sinko PJ Drug Deliv Transl Res; 2022 Jan; 12(1):240-256. PubMed ID: 33590464 [TBL] [Abstract][Full Text] [Related]
15. Inhibition of presenilins attenuates proliferation and invasion in bladder cancer cells through multiple pathways. Gai JW; Wahafu W; Hsieh YC; Liu M; Zhang L; Li SW; Zhang B; He Q; Guo H; Jin J Urol Oncol; 2014 Jan; 32(1):36.e19-25. PubMed ID: 23628311 [TBL] [Abstract][Full Text] [Related]
16. Celecoxib inhibits N-butyl-N-(4-hydroxybutyl)-nitrosamine-induced urinary bladder cancers in male B6D2F1 mice and female Fischer-344 rats. Grubbs CJ; Lubet RA; Koki AT; Leahy KM; Masferrer JL; Steele VE; Kelloff GJ; Hill DL; Seibert K Cancer Res; 2000 Oct; 60(20):5599-602. PubMed ID: 11059745 [TBL] [Abstract][Full Text] [Related]
17. Inhibitory effects of the aqueous extract of Magnolia officinalis on the responses of human urinary bladder cancer 5637 cells in vitro and mouse urinary bladder tumors induced by N-Butyl-N-(4-hydroxybutyl) nitrosamine in vivo. Lee SJ; Cho YH; Park K; Kim EJ; Kang BS; Jung KH; Kim CH; Kim WJ; Moon SK Phytother Res; 2009 Jan; 23(1):20-7. PubMed ID: 19048611 [TBL] [Abstract][Full Text] [Related]
18. Repositioning the Old Fungicide Ciclopirox for New Medical Uses. Shen T; Huang S Curr Pharm Des; 2016; 22(28):4443-50. PubMed ID: 27238364 [TBL] [Abstract][Full Text] [Related]
19. Ciclopirox olamine promotes the angiogenic response of endothelial cells and mesenchymal stem cells. Kremer A; Wußmann M; Herrmann M; Raghunath M; Walles H Clin Hemorheol Microcirc; 2019; 73(2):317-328. PubMed ID: 31006674 [TBL] [Abstract][Full Text] [Related]
20. Evaluation of selective gamma-secretase inhibitor PF-03084014 for its antitumor efficacy and gastrointestinal safety to guide optimal clinical trial design. Wei P; Walls M; Qiu M; Ding R; Denlinger RH; Wong A; Tsaparikos K; Jani JP; Hosea N; Sands M; Randolph S; Smeal T Mol Cancer Ther; 2010 Jun; 9(6):1618-28. PubMed ID: 20530712 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]